KINDReD – “Kinetoplastid Drug Development: strengthening the preclinical pipeline” is a research project funded by the Seventh Framework Programme of the European Union under Grant agreement number 602773.

 

The trypanosomatid diseases, leishmaniasis, Human African trypanosomiasis (HAT) and Chagas disease (CD) continue to impart a heavy toll on human health. The treatments available are limited and threatened by drug resistance with few new drugs in the pipeline.

The KINDReD consortium integrates academic and industrial researchers from 14 institutions and 9 countries, joining efforts to strengthen the drug development pipeline aiming to achieve at least one new Phase 1 clinical candidate for each trypanosomatid disease. This September meeting is an opportunity to review the project’s progress one year after its start.